ALSUntangled #70: caffeine

Jessica Hatch, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Paul Barkhaus, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
Benjamin Barnes, Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
Morgan Beauchamp, Neurosciences Clinical Trials Unit, UNC, Chapel Hill, NC, USA.
Michael Benatar, Department of Neurology, University of Miami, Miami, FL, USA.
Tulio Bertorini, Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
Robert Bowser, Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.Follow
Mark Bromberg, Department of Neurology, University of Utah, Salt Lake City, UT, USA.
Andrew Brown, Department of Neurology, University of Miami, Miami, FL, USA.
Javier Mascias Cadavid, ALS Department, Hospital Carlos III-La Paz, Madrid, Spain.
Gregory T. Carter, Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
Nicholas Cole, Motor Neurone Disease Association, Northampton, UK.Follow
Jesse Crayle, Department of Neurology, Washington University, St. Louis, MO, USA.
Mazen Dimachkie, Department of Neurology, University of Kansas, Kansas City, KS, USA.
David Ennist, Origent Data Sciences, Inc, Vienna, VA, USA.
Eva Feldman, Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
Timothy Fullam, Department of Neurology, University of Texas, San Antonio, TX, USA.
Terry Heiman-Patterson, Department of Neurology, Temple Health, Philadelphia, PA, USA.
Sartaj Jhooty, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Todd Levine, Bob Bove Neuroscience Institute, Scottsdale, AZ, USA.
Xiaoyan Li, Department of Neurology, Duke University, Durham, NC, USA.
Isaac Lund, Green Hope High School, Cary, NC, USA.
Elise Mallon, Duke University, Durham, NC, USA.
Nicholas Maragakis, Department of Neurology, Johns Hopkins, Baltimore, MD, USA.
Christopher McDermott, Department of Neuroscience, University of Sheffield, Sheffield, UK.
Gary Pattee, Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
Kaitlyn Pierce, Department of Neuroscience, University of North Carolina, Chapel Hill, NC, USA.
Dylan Ratner, Tulane University, New Orleans, LA, USA.
Kim Staats, Staats Life Consulting, Los Angeles, CA, USA.
Paul Wicks, Independent Consultant, Lichfield, UK, and.
Martina Wiedau, Department of Neurology, University of California, Los Angeles, CA, USA.
Richard Bedlack, Department of Neurology, Duke University, Durham, NC, USA.

Document Type

Article

Abstract

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here, we review caffeine which has plausible mechanisms for slowing ALS progression. However, pre-clinical studies are contradictory, and a large case series showed no relationship between caffeine intake and ALS progression rate. While low doses of caffeine are safe and inexpensive, higher doses can cause serious side effects. At this time, we cannot endorse caffeine as a treatment to slow ALS progression.

Keywords

Amyotrophic lateral sclerosis (ALS), adenosine, caffeine, coffee, tea

Publication Date

6-8-2023

Publication Title

Amyotrophic lateral sclerosis & frontotemporal degeneration

E-ISSN

2167-9223

First Page

1

Last Page

5

PubMed ID

37288776

Digital Object Identifier (DOI)

10.1080/21678421.2023.2220742

Link to Full Text

Share

COinS